Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIIP siRNA is a small interfering RNA (siRNA) used as a research tool to silence the expression of the Migration and Invasion Inhibitory Protein (MIIP) gene. MIIP is a putative tumor suppressor gene that has been shown to inhibit cell motility, invasion, and proliferation in various cancers, including endometrial carcinoma. In research settings, knockdown of MIIP using siRNA has been observed to significantly increase cell migration and invasion, while reducing the levels of matrix metalloproteases such as MMP-2 and MMP-9. This reagent is primarily used in in vitro studies to elucidate the role of MIIP in oncogenic pathways such as TP53, Jak-STAT, and PI3K/Akt signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MIIP siRNA.